The current study includes mercuration and telluration of some sulpha compounds; these compounds were prepared by reaction of 4-aminobenzenesulfonic acid and 4,4'-sulfonyldianiline with mercuric(II) acetate reagent to produce Arylmercuric(II)chloride, which was subjected to transmetallation reactions by using TeBr4 to form the Aryltellurium(IV) tribromide. Additionally, the reactions between (2-amino-5-sulfophenyl)mercury(II) chloride and 3,4-dihydroxybenzaldehyde on one hand, and 4,4'-sulfonylbis[2-chloromercuric aniline] with benzaldehyde, on the other, produce mercurated sulpha compounds containing azomethine- group. These obtained compounds react with TeBr4 to form new tellurated sulpha compounds containing azomethine-group. These newly created compounds were subjected to various analyses, including C.H.N.S analysis, proton-NMR, FT-IR, and Carbon-13 NMR. The synthesised compounds were tested for cytotoxicity using in-vitro analyses on two human cancer cell lines, PC3 (prostate cancer cell) and T24 (bladder cancer cell). The prepared organotellurium compounds are effective, especially 4 and 6 compounds. DFT calculations of HOMO and LUMO energy levels and certain quantum parameters indicate that the organomercury compounds are relatively stable and exhibit lesser reactivity when compared to their organotellurium counterparts. Additionally, theoretical results validate the results obtained by the measurement of cancer effectiveness.